Researchers have found that dupilumab may reduce or eliminate vascular leakage of plasma proteins into the skin of patients with atopic dermatitis, according to a study published by Leung et al in The Journal of Allergy and Clinical Immunology. Researchers analyzed the plasma protein composition of skin tapes from patients with moderate-to-severe atopic dermatitis who had either lesional and nonlesional skin and were undergoing treatment with dupilumab, and compared the results with those of controls. At baseline, 115 plasma proteins were detected in patients with atopic dermatitis—a 1.5-fold higher count than the plasma proteins detected in controls. However, after the patients were treated with dupilumab for 16 weeks, most of the patients saw their plasma protein levels—especially fibrinogen gamma, beta chains, alpha2-macroglobulin, serotransferrin, and complement C3—reduce to similar levels as controls. The researchers concluded that dupilumab may offer significant benefit in decreasing the vascular leakage of plasma proteins associated with atopic dermatitis.